The Oncology Institute Rebrands Clinical Trials Division
December 15 2022 - 8:00AM
The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest
value-based community oncology groups in the United States, is
rebranding its clinical research division. Previously, TOI’s
clinical research division was named Innovative Clinical Research
Institute (ICRI). The division’s new name is TOI Clinical Research.
TOI Clinical Research will carry on the important work ICRI has
been conducting since its founding in 2011. TOI Clinical Research
currently manages over 160 clinical trials across solid tumors and
hematological malignancies. TOI Clinical Research will follow the
same successful model that helped build ICRI into a leader in the
field of cancer clinical trials, relying on a network of
compassionate, experienced cancer care specialists dedicated to
providing clinical trials as a treatment option.
“Our clinical trials program is part of what makes The Oncology
Institute a leader in the value-based cancer care industry,” TOI
Chief Medical Officer Dr. Yale Podnos said. “TOI Clinical Research
continues the great work that our Innovative Clinical Research
Institute started as one of the largest community-based clinical
trials programs in the country, improving access to the latest
treatments and increasing scientific knowledge in cancer
therapy.”
As TOI Clinical Research grows in 2023, there will be a
continued commitment to streamlined screening of TOI patients for
eligibility for appropriate trials, expanding access at more sites
across the country, and improving health equity by offering these
treatments in underserved and diverse communities.
“Our primary goal is to offer patients access to a variety of
treatment options designed to support improvements in health
outcomes,” said Cristina Green, TOI Vice President of Clinical
Research. “Through our strategic partnerships with the
biopharmaceutical industry and software providers, we are well
positioned to offer the latest in both treatments and care delivery
platforms.”
About TOIFounded in 2007, TOI is advancing
oncology by delivering highly specialized, value-based cancer care
in the community setting. TOI offers cutting-edge, evidence-based
cancer care to a population of approximately 1.7 million patients
including clinical trials, transfusions, and other care delivery
models traditionally associated with the most advanced care
delivery organizations. With 90+ employed clinicians and more than
700 teammates in over 50 clinic locations and growing, TOI is
changing oncology for the better. For more information visit
www.theoncologyinstitute.com.
Contacts
MediaThe Oncology InstituteJulie
KorinkeJulieKorinke@theoncologyinstitute.com(562) 735-3226 x
88806
InvestorsSolebury TroutMaria
Lycourismlycouris@soleburytrout.com
Oncology Institute (NASDAQ:TOIIW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Oncology Institute (NASDAQ:TOIIW)
Historical Stock Chart
From Jul 2023 to Jul 2024